MX2017004592A - Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. - Google Patents

Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.

Info

Publication number
MX2017004592A
MX2017004592A MX2017004592A MX2017004592A MX2017004592A MX 2017004592 A MX2017004592 A MX 2017004592A MX 2017004592 A MX2017004592 A MX 2017004592A MX 2017004592 A MX2017004592 A MX 2017004592A MX 2017004592 A MX2017004592 A MX 2017004592A
Authority
MX
Mexico
Prior art keywords
peptide
pharmaceutically acceptable
complex
pharmaceutical formulations
oral delivery
Prior art date
Application number
MX2017004592A
Other languages
English (en)
Spanish (es)
Inventor
Föger Florian
Original Assignee
Cyprumed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51751911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017004592(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cyprumed Gmbh filed Critical Cyprumed Gmbh
Publication of MX2017004592A publication Critical patent/MX2017004592A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2017004592A 2014-10-07 2015-10-07 Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. MX2017004592A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14187885.0A EP3006045B3 (en) 2014-10-07 2014-10-07 Pharmaceutical formulations for the oral delivery of peptide or protein drugs
PCT/EP2015/073196 WO2016055550A1 (en) 2014-10-07 2015-10-07 Pharmaceutical formulations for the oral delivery of peptide or protein drugs

Publications (1)

Publication Number Publication Date
MX2017004592A true MX2017004592A (es) 2017-07-10

Family

ID=51751911

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004592A MX2017004592A (es) 2014-10-07 2015-10-07 Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.

Country Status (16)

Country Link
US (1) US20170304195A1 (cg-RX-API-DMAC7.html)
EP (2) EP3006045B3 (cg-RX-API-DMAC7.html)
JP (1) JP2017531665A (cg-RX-API-DMAC7.html)
KR (1) KR20170061140A (cg-RX-API-DMAC7.html)
CN (1) CN106794252A (cg-RX-API-DMAC7.html)
AU (1) AU2015330016A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017006957A2 (cg-RX-API-DMAC7.html)
CA (1) CA2960334A1 (cg-RX-API-DMAC7.html)
DK (1) DK3006045T3 (cg-RX-API-DMAC7.html)
ES (1) ES2630106T3 (cg-RX-API-DMAC7.html)
IL (1) IL251462A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017004592A (cg-RX-API-DMAC7.html)
RU (1) RU2017115651A (cg-RX-API-DMAC7.html)
SG (1) SG11201702813VA (cg-RX-API-DMAC7.html)
WO (1) WO2016055550A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701719B (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
EP3359181A1 (en) * 2015-10-07 2018-08-15 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide drugs
ES2904891T3 (es) 2016-04-18 2022-04-06 Radius Health Inc Formulaciones de abaloparatida, parche transdérmico de la misma y usos de la misma
EP4265296A3 (en) * 2016-09-29 2023-12-20 Arecor Limited Pharmaceutical formulation comprising an insulin compound
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
SG10201609137PA (en) * 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Gamma-polyglutamic acid and zinc compositions
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
CN109381695A (zh) * 2017-08-09 2019-02-26 武汉武药科技有限公司 一种门冬氨酸帕瑞肽注射液及其制备方法和用途
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
TWI751379B (zh) * 2017-09-21 2022-01-01 奧孟亞股份有限公司 用於遞送胜肽之藥物組合物
WO2019078663A2 (ko) * 2017-10-20 2019-04-25 주식회사 노브메타파마 아연염, 시클로-히스프로 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
CN108079280B (zh) * 2017-12-30 2021-06-04 陕西慧康生物科技有限责任公司 治疗ⅱ型糖尿病的艾塞那肽滴鼻剂
US12649000B2 (en) 2018-03-19 2026-06-09 Algipharma As Use of alginate oligomers to enhance the translocation of micro/nanoparticles across mucus layers
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN108721598B (zh) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 一种缩宫素原料的制备方法及其药物组合物和制剂
PL3886814T3 (pl) 2018-11-26 2025-04-07 The Procter & Gamble Company Stały preparat farmaceutyczny zawierający kwas liponowy i jego zastosowanie
CN110251661B (zh) * 2018-12-12 2022-09-16 福州市台江区希吉亚健康科技有限公司 一种用于治疗糖尿病或者减肥的药物制剂
CN110251662B (zh) * 2018-12-12 2023-01-31 福州市台江区希吉亚健康科技有限公司 一种具有减肥作用的药物
KR102327750B1 (ko) * 2018-12-19 2021-11-18 대화제약 주식회사 Glp-1 유사체를 포함하는 경구투여용 약제학적 조성물
WO2020183318A1 (en) * 2019-03-08 2020-09-17 Anya Biopharm Inc. Oral formulation and treatment of pth analog.
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
CN112138148B (zh) * 2019-06-10 2024-04-09 苏州兰鼎生物制药有限公司 一种生长激素或其类似物的口服药物组合物
CN112057619A (zh) * 2019-06-10 2020-12-11 苏州兰鼎生物制药有限公司 一种具有降血糖作用的药物组合物
WO2020257260A1 (en) 2019-06-17 2020-12-24 Massachusetts Institute Of Technology Formulation of peptide loaded liposomes and related applications
JP7311086B2 (ja) * 2019-08-21 2023-07-19 ブレイン ケミストリー ラブズ 金属及びl-セリンを含む組成物、並びにその使用
KR102216578B1 (ko) * 2019-09-05 2021-02-17 주식회사 아이큐어비앤피 테리파라타이드를 포함하는 경구용 약학 조성물 및 이의 제조방법
EP4029493A4 (en) 2019-09-09 2023-10-04 Taejoon Pharmaceutical Co., Ltd. OPHTHALMIC NANOEMULSION COMPOSITION WITH CYCLOSPORIN AND MENTHOL AND METHOD FOR THE PRODUCTION THEREOF
CN113509544B (zh) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 一种具有降血糖作用的药物组合物
CN112972659A (zh) * 2019-12-14 2021-06-18 苏州兰鼎生物制药有限公司 一种特立帕肽或阿巴洛肽的口服药物组合物
CN112972650B (zh) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 一种生长抑素或其类似物的口服药物组合物
CN112972658B (zh) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 一种生长激素或其类似物的口服药物组合物
CN112972692A (zh) * 2019-12-14 2021-06-18 苏州兰鼎生物制药有限公司 一种促进肠吸收的药物组合物
CN112972656B (zh) * 2019-12-14 2024-04-09 苏州兰鼎生物制药有限公司 一种胰高血糖素样肽-2或其类似物的口服药物组合物
CN113171446B (zh) * 2021-05-06 2022-03-29 合肥天汇孵化科技有限公司 利拉鲁肽组合物及其用途
CN116262134A (zh) * 2021-12-15 2023-06-16 联邦生物科技(珠海横琴)有限公司 一种稳定的多剂量给药的glp-1受体激动剂的制剂及其制备方法和应用
EP4226918A1 (en) * 2022-02-15 2023-08-16 Filip Majewski Pharmaceutical single dosage form for oral delivery of peptides
KR102492241B1 (ko) * 2022-02-25 2023-01-30 전남대학교산학협력단 Kitenin의 이량체 형성을 저해하는 펩타이드 및 이의 용도
TW202400219A (zh) * 2022-04-29 2024-01-01 香港商鵬躍醫藥科技有限公司 用於鼻內給藥的索馬魯肽及其鹽的藥物組合物
CN115161253B (zh) * 2022-05-30 2022-12-02 微康益生菌(苏州)股份有限公司 一种保持细胞结构完整性的益生菌灭活方法及其应用
CN117357633A (zh) * 2022-06-30 2024-01-09 深圳翰宇药业股份有限公司 二硫基脂肪酸及其盐在口服递送蛋白质或多肽类药物中的应用
EP4299071A1 (en) * 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物
WO2024010379A1 (ko) * 2022-07-05 2024-01-11 주식회사 지투지바이오 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방성 미립구 제제 및 이의 제조방법
KR102844771B1 (ko) * 2022-07-22 2025-08-12 주식회사 아이큐어비앤피 테리파라타이드를 포함하는 골다공증 예방 또는 치료를 위한 경구용 약학적 조성물 및 이의 제조방법
CN116271064A (zh) * 2022-09-09 2023-06-23 中山大学·深圳 一种促进利拉鲁肽安全渗透肠细胞的辅料组合物
WO2024077409A1 (en) * 2022-10-09 2024-04-18 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
KR102590243B1 (ko) * 2023-03-13 2023-10-20 주식회사 에코월드팜 수면장애 개선을 위한 l-트립토판 및 키토산을 포함하는 조성물
CN121358465A (zh) 2023-04-26 2026-01-16 维沃特克斯公司 用于改善渗透的治疗剂的调配物
WO2025037993A1 (en) * 2023-08-13 2025-02-20 Filip Majewski Dosage form for peptide agents
CN119454605B (zh) * 2023-11-30 2025-12-19 深圳奥礼生物科技有限公司 一种实现多肽口服吸收的组合物
CN118001411A (zh) * 2024-04-09 2024-05-10 深圳奥礼生物科技有限公司 一种肠道吸收组合物
CN118105468B (zh) * 2024-04-23 2024-07-16 长春生物制品研究所有限责任公司 重组人干扰素α2a栓及制备方法
US12544349B1 (en) 2024-12-30 2026-02-10 Adocia Compositions comprising pemvidutide and an acylated amino acid

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
DE69916811T2 (de) 1998-02-27 2005-04-14 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US20020009490A1 (en) * 1999-12-22 2002-01-24 Benkendorfer Travis R. Antiviral therapeutic composition and treatment
US20010012829A1 (en) * 2000-01-11 2001-08-09 Keith Anderson Transepithelial delivery GLP-1 derivatives
WO2003007913A2 (en) 2001-07-20 2003-01-30 Samir Mitragotri Method for oral drug delivery
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1686982A4 (en) * 2003-11-19 2007-03-21 Vecta Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HELICOBACTER PYLORI USING COMPOUNDS CONTAINING ENDOPEROXIDE BRIDGE
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
JP2007537141A (ja) 2003-12-18 2007-12-20 ノボ ノルディスク アクティーゼルスカブ 新規なglp−1化合物
WO2005113592A2 (en) * 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
ES2542228T3 (es) 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
JP2006028031A (ja) * 2004-07-12 2006-02-02 Ltt Bio-Pharma Co Ltd 経粘膜吸収用薬物封入ナノ粒子
CN101027318B (zh) * 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
CA2578748C (en) 2004-09-03 2014-10-14 Kyowa Hakko Kogyo Co., Ltd. Composition and method for prevention or treatment of stomatitis
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー/エス 遅延性のエキセンディン−4化合物
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性glp−1化合物
WO2006082245A1 (en) 2005-02-07 2006-08-10 Novo Nordisk A/S Pharmaceutical preparations comprising insulin, zinc ions and a zinc-binding ligand
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
ES2484796T3 (es) 2005-03-18 2014-08-12 Novo Nordisk A/S Compuestos de GLP-1 extendidos
US7618669B2 (en) * 2005-06-01 2009-11-17 Mead Johnson Nutrition Company Low-lactose partially hydrolyzed infant formula
EP2722054B1 (en) 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US20090214657A1 (en) * 2005-11-30 2009-08-27 Muhammad Waseem Tahir Qazi Orally Absorbed Pharmaceutical Formulation and Method of Administration
GB0525461D0 (en) * 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
RS60101B1 (sr) * 2008-08-15 2020-05-29 Ironwood Pharmaceuticals Inc Formulacije koje sadrže linaklotid za oralnu primenu
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
CN102596253B (zh) 2009-09-30 2013-11-06 蒂奥迈里克斯研究与指导有限公司 含有维生素b 亚结构的粘膜粘着聚合物
WO2011116139A2 (en) * 2010-03-16 2011-09-22 Chiasma Inc. Improved pharmaceutical compositions and methods of delivery
KR20130100897A (ko) 2010-04-21 2013-09-12 나노메가 메디컬 코포레이션 나노입자의 약제학적 조성물
AU2011252127B2 (en) 2010-05-10 2014-02-20 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
TW201202178A (en) * 2010-06-04 2012-01-16 Chemo Iberica Sa Process for producing Aliskiren
MX377589B (es) * 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
JP2014502984A (ja) * 2011-01-19 2014-02-06 ノヴォ ノルディスク アー/エス Glp−1組成物
WO2012112319A1 (en) 2011-02-04 2012-08-23 Aegis Therapeutics, Llc Orally bioavailable peptide drug compositions and methods thereof
CN103458873B (zh) 2011-04-14 2016-04-13 诺沃—诺迪斯克有限公司 用于口服肽递送的脂肪酸酰化的氨基酸
WO2012170828A1 (en) * 2011-06-10 2012-12-13 Monosol Rx, Llc Combination peptide-nanoparticles and delivery systems incorporating same
US20130004590A1 (en) 2011-06-28 2013-01-03 Lin Connie B Zinc oxide/acid containing compositions and methods for treating and/or preventing enzymatic irritation
BR112014005091A2 (pt) * 2011-09-05 2017-06-13 Beijing Hanmi Pharmaceutical Co Ltd composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Glp-1 펩티드의 조성물 및 그것의 제조
US20150174076A1 (en) 2012-06-14 2015-06-25 Entrega, Inc. Mucoadhesive devices for delivery of active agents
HK1215934A1 (zh) * 2012-12-06 2016-09-30 Stealth Peptides International, Inc. 肽治疗剂及其使用方法
CN103948915B (zh) * 2014-05-05 2016-06-22 德立唯(北京)生物科技有限公司 一种能够提高稳定性和口服疗效的用于预防血栓形成和溶栓的纳豆激酶组合物
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs

Also Published As

Publication number Publication date
EP3204045B1 (en) 2018-12-05
ZA201701719B (en) 2018-05-30
EP3204045A1 (en) 2017-08-16
AU2015330016A1 (en) 2017-04-20
DK3006045T3 (en) 2017-07-17
EP3006045A1 (en) 2016-04-13
JP2017531665A (ja) 2017-10-26
BR112017006957A2 (pt) 2017-12-19
WO2016055550A1 (en) 2016-04-14
EP3006045B3 (en) 2021-03-17
IL251462A0 (en) 2017-05-29
RU2017115651A (ru) 2018-11-20
SG11201702813VA (en) 2017-05-30
KR20170061140A (ko) 2017-06-02
US20170304195A1 (en) 2017-10-26
EP3006045B1 (en) 2017-04-12
CN106794252A (zh) 2017-05-31
CA2960334A1 (en) 2016-04-14
ES2630106T3 (es) 2017-08-18

Similar Documents

Publication Publication Date Title
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
MY187047A (en) Selective pyy compounds and uses thereof
JP2015517488A5 (cg-RX-API-DMAC7.html)
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
PH12014500386A1 (en) Combination treatment for hepatitis c
JP2013520405A5 (cg-RX-API-DMAC7.html)
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
IN2014DN06920A (cg-RX-API-DMAC7.html)
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
EP3162804A8 (en) New benzodiazepine derivative and use thereof
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX376783B (es) Liposomas que encapsulan un autoantígeno y su uso en la prevención y/o el tratamiento de enfermedades autoinmunes.
JP2016512247A5 (cg-RX-API-DMAC7.html)
MX374938B (es) Un método para el tratamiento de trastornos del movimiento con befiradol.
MX2017014776A (es) Combinacion farmaceutica de everolimus con dactolisib.
IN2014DN09240A (cg-RX-API-DMAC7.html)
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite
MX2015009681A (es) Un medicamento combinado que comprende finilefrina y paracetamol.
WO2015130963A3 (en) Compositions and methods for administering insulin or insulin-like protein to the brain
IN2012CH05549A (cg-RX-API-DMAC7.html)